Authors:

Thomas Eko P

Abstract:

“The advent of the Coxibs (COX-2 inhibitor) represented a significant theorical breakthrough in non-steroid anti inflammatory drugs (NSAIDs) treatment. The use of NSAIDs is limited by by adverse reactions, especially their gastrointestinal (GI) toxicity. The selective COX-2 inhibitors were originally developed to minimize the adverse effect of conventional NSAIDs while maintaining the same analgesic and anti-inflammatory effects. Although the benefit of coxibs in GI tract has been established the cardiovascular (CV) safety of coxibs still debatable. Several studies have reported an increased incidence of cardiovascular related morbidity and mortality with the use of COX-2 inhibitor. A definitive answer to whether or not these drugs increase CV risk can only really be derived from multicenter purpose-designed, prospective randomized control trials. Circumstances under which COX-2 selective inhibitor maybe appropriate are in patients at high GI risk and in patients who did not respond to multiple conventional NSAIDs. Health care providers must consider the efficacy, GI and CV risks, concomitant medications and costs when determining the appropriateness of COX-2 selective inhibitor therapy.(MEDICINA 2012;43:23-30).”

Keywords

Keyword Not Available

Downloads:

Download data is not yet available.

References

References Not Available

PDF:

https://jurnal.harianregional.com/medicina/full-4947

Published

2021-11-09

How To Cite

EKO P, Thomas. THE USE COXIB IN NOCICEPTIVE PAIN MANAGEMENT.Medicina, [S.l.], v. 43, n. 1, mar. 2013. ISSN 2540-8321. Available at: https://jurnal.harianregional.com/medicina/id-4947. Date accessed: 28 Aug. 2025.

Citation Format

ABNT, APA, BibTeX, CBE, EndNote - EndNote format (Macintosh & Windows), MLA, ProCite - RIS format (Macintosh & Windows), RefWorks, Reference Manager - RIS format (Windows only), Turabian

Issue

Vol 43 No 1 (2012): Januari 2012

Section

Articles

Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License